CN1293874C - 以洛伐他汀盐为主要活性成分的中药红曲及其制剂 - Google Patents
以洛伐他汀盐为主要活性成分的中药红曲及其制剂 Download PDFInfo
- Publication number
- CN1293874C CN1293874C CNB03135632XA CN03135632A CN1293874C CN 1293874 C CN1293874 C CN 1293874C CN B03135632X A CNB03135632X A CN B03135632XA CN 03135632 A CN03135632 A CN 03135632A CN 1293874 C CN1293874 C CN 1293874C
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- salt
- monascus
- lovastatin
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 244000113306 Monascus purpureus Species 0.000 title claims description 31
- 235000002322 Monascus purpureus Nutrition 0.000 title claims description 29
- 229940057059 monascus purpureus Drugs 0.000 title claims description 28
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical class C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 title abstract description 34
- 241000228347 Monascus <ascomycete fungus> Species 0.000 claims abstract description 25
- 239000000284 extract Substances 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 37
- 150000001875 compounds Chemical class 0.000 claims description 14
- LXZBFUBRYYVRQJ-AXHZAXLDSA-M sodium;(3r,5r)-7-[(1s,2s,6r,8s,8ar)-2,6-dimethyl-8-[(2s)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate Chemical compound [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@@H](C)C=C21 LXZBFUBRYYVRQJ-AXHZAXLDSA-M 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 239000007787 solid Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000000855 fermentation Methods 0.000 claims description 5
- 230000004151 fermentation Effects 0.000 claims description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 150000002596 lactones Chemical class 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 239000007790 solid phase Substances 0.000 claims description 3
- 230000036983 biotransformation Effects 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- -1 lovastatin sodium salt chemical compound Chemical class 0.000 claims description 2
- 239000012567 medical material Substances 0.000 claims description 2
- 229930014626 natural product Natural products 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims 1
- 239000002775 capsule Substances 0.000 abstract description 9
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract description 7
- 239000008187 granular material Substances 0.000 abstract description 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract description 7
- 239000006187 pill Substances 0.000 abstract description 7
- 239000000843 powder Substances 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 2
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 26
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 23
- 229960004844 lovastatin Drugs 0.000 description 21
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000000463 material Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 239000008802 xuezhikang Substances 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 239000008118 PEG 6000 Substances 0.000 description 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003810 ethyl acetate extraction Methods 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 150000001261 hydroxy acids Chemical class 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229940099246 mevacor Drugs 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 206010020466 Hunger Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000059961 Monascus barkeri Species 0.000 description 1
- 241000031003 Monascus ruber Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 235000007189 Oryza longistaminata Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000237636 Pheretima Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002402 anti-lipaemic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000000110 cooling liquid Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229930185723 monacolin Natural products 0.000 description 1
- XXKNHBAFFJINCK-RVEJDSBJSA-N monascin Chemical compound C([C@@H]1[C@H](C(O[C@@]1(C)C1=O)=O)C(=O)CCCCC)C2=C1COC(\C=C\C)=C2 XXKNHBAFFJINCK-RVEJDSBJSA-N 0.000 description 1
- GFSMXLMQRWMHON-UHFFFAOYSA-N monascin Natural products CCCCCC(=O)C1C2C=C3C=C(OC=C3C(=O)C2(C)OC1=O)C=CC GFSMXLMQRWMHON-UHFFFAOYSA-N 0.000 description 1
- GIKQHOXMDCDAPT-UHFFFAOYSA-N monascusone B Natural products CC=CC1=CC2=C(CO1)C(=O)C3(C)OC(=O)C(C3C2)C(=O)C GIKQHOXMDCDAPT-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940026314 red yeast rice Drugs 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010563 solid-state fermentation Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB03135632XA CN1293874C (zh) | 2003-08-18 | 2003-08-18 | 以洛伐他汀盐为主要活性成分的中药红曲及其制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB03135632XA CN1293874C (zh) | 2003-08-18 | 2003-08-18 | 以洛伐他汀盐为主要活性成分的中药红曲及其制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1513451A CN1513451A (zh) | 2004-07-21 |
CN1293874C true CN1293874C (zh) | 2007-01-10 |
Family
ID=34240039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB03135632XA Expired - Lifetime CN1293874C (zh) | 2003-08-18 | 2003-08-18 | 以洛伐他汀盐为主要活性成分的中药红曲及其制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1293874C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100336517C (zh) * | 2005-07-29 | 2007-09-12 | 南京海陵中药制药工艺技术研究有限公司 | 预防或治疗心脑血管疾病的红曲、银杏叶组合物及其应用 |
CN1919214B (zh) * | 2005-08-24 | 2010-05-05 | 成都地奥九泓制药厂 | 一种红曲软胶囊及其制备方法 |
CN100451644C (zh) * | 2005-12-19 | 2009-01-14 | 北京维信学知科技发展有限公司 | 一种血脂康胶囊的质量检测方法 |
CN103372040B (zh) * | 2012-04-20 | 2016-01-27 | 北京北大维信生物科技有限公司 | 一种调节血脂的红曲川芎药物组合及其制备方法 |
CN105054021A (zh) * | 2015-08-04 | 2015-11-18 | 江苏大学 | 一种红曲霉转化玉米皮发酵液的制备方法及其应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1368948A (zh) * | 1999-08-06 | 2002-09-11 | 莱克制药与化学公司 | 普伐他汀钠盐晶体 |
-
2003
- 2003-08-18 CN CNB03135632XA patent/CN1293874C/zh not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1368948A (zh) * | 1999-08-06 | 2002-09-11 | 莱克制药与化学公司 | 普伐他汀钠盐晶体 |
Also Published As
Publication number | Publication date |
---|---|
CN1513451A (zh) | 2004-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5165894B2 (ja) | 体脂肪率減少薬剤 | |
JP2003521217A (ja) | 赤米の発酵生成物を用いる方法及び組成物 | |
CN105395919B (zh) | 一种含有黑木耳提取物、具有降血脂作用的组合物及其制备方法 | |
JP2007520418A (ja) | 酢を利用した人参製剤及びこれの製造方法 | |
CN106963820A (zh) | 胡椒属植物精油的用途 | |
CN103417753A (zh) | 一种具有保护心脑血管作用的植物油组合物及其制备方法与应用 | |
KR20120003693A (ko) | 적포도 추출물, 녹차 추출물, 대두 추출물 및 l-카르니틴을 유효성분으로 함유하는 항비만 조성물 | |
CN102697982B (zh) | 一种具有辅助降血脂功能的组合物及其制备方法 | |
CN1293874C (zh) | 以洛伐他汀盐为主要活性成分的中药红曲及其制剂 | |
CN100342861C (zh) | 一种红曲提取物及其制剂 | |
KR100828068B1 (ko) | 푸코잔틴 또는 이를 함유하는 해조류 추출물을 포함하는,고지혈증의 예방 또는 치료용 조성물 | |
CN102949535A (zh) | 一种抗高血脂及动脉粥样硬化的中药制剂及其制备方法 | |
CN110051817A (zh) | 一种降低尿酸的中药组合及其应用 | |
CN109966373A (zh) | 一种黑果枸杞籽油提取物在降血脂药物中的应用 | |
CN114259526A (zh) | 一种降血脂类药物或降血脂保健品的配方及其制作方法 | |
CN101361800A (zh) | 降血脂及增效减毒他汀类药物作用的中药及其制备方法 | |
CN103054906A (zh) | 用于解酒的蜂胶乙醇提取物、制备方法及在生产口含片中的应用 | |
JP3495694B2 (ja) | 薬用人参、西洋人参及び田七人参などからなる生薬及びその抽出物、食品、医薬部外品並びに医薬品 | |
CN1660207A (zh) | 降低血脂和胆固醇的保健制剂及其生产方法 | |
CN105902601B (zh) | 酸角壳提取物在制备降血脂药物中的应用 | |
CN101053598B (zh) | 一种防治心脑血管疾病及糖尿病的药物组合物 | |
JP2008088131A (ja) | 抗コレステロール組成物 | |
KR102161893B1 (ko) | 잣나무 부산물 추출물을 포함하는 항비만용 조성물 | |
CN1333047A (zh) | 云南松籽提取物及其制备方法和应用 | |
CN112089783B (zh) | 中药组合物在制备预防或/和治疗肥胖的药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: KUNMING FAMOTAIKE BIOTECHNOLOGY Co.,Ltd. Assignor: Li Chaohui|Wang Lixin Contract fulfillment period: 2009.9.1 to 2019.9.1 Contract record no.: 2009530000044 Denomination of invention: Traditional chinese medicine Monascus purpureus went using Lovastatin salt as main active and its preparation component Granted publication date: 20070110 License type: Exclusive license Record date: 20091019 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.9.1 TO 2019.9.1; CHANGE OF CONTRACT Name of requester: KUMING FAMOTECH BIOISYSTECH CO., LTD. Effective date: 20091019 |
|
ASS | Succession or assignment of patent right |
Owner name: KUNMING FAMOTAIKE BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: LI ZHAOHUI Effective date: 20150603 Free format text: FORMER OWNER: WANG LIXIN Effective date: 20150603 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 650200 KUNMING, YUNNAN PROVINCE TO: 650106 KUNMING, YUNNAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150603 Address after: Two, No. four, No. 402-1, building A2, 650106, University Science Park, Kunming hi tech Development Zone, Yunnan, China Patentee after: KUNMING FAMOTAIKE BIOTECHNOLOGY Co.,Ltd. Address before: 650200 No. 25, No. 4-302, Yinhai forest, Tengchong County, Yunnan, Kunming Patentee before: Li Chaohui Patentee before: Wang Lixin |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20151228 Address after: Qujing City, Yunnan province 655000 kylin District Jianning Road Patentee after: YUNNAN YONGAN PHARMACEUTICAL Co.,Ltd. Address before: Two, No. four, No. 402-1, building A2, 650106, University Science Park, Kunming hi tech Development Zone, Yunnan, China Patentee before: KUNMING FAMOTAIKE BIOTECHNOLOGY Co.,Ltd. |
|
CX01 | Expiry of patent term |
Granted publication date: 20070110 |
|
CX01 | Expiry of patent term |